A Phase 3 interventional study of Maraviroc + Zidovudine/Lamivudine and Efavirenz + Zidovudine/Lamivudine in HIV-1, sponsored by ViiV Healthcare. Completed at 144 sites in 14 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2013-10-09.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Maraviroc (UK-427,857), a selective and reversible CCR5 coreceptor antagonist, has been shown to be active in vitro against a wide range of clinical isolates (including those resistant to existing classes). In HIV-1 infected patients, maraviroc (UK-427,857) given as monotherapy for 10 days reduced HIV-1 viral load by up to 1.6 log, consistent with currently available agents. Safety and toleration have been studied in over 400 subjects for up to 28 days at 300 mg twice daily. No significant effects were seen on the QTc interval. The goal of this study is to compare the safety and efficacy of maraviroc (UK-427,857) versus efavirenz, when each are combined with two other antiretroviral agents, in patients who are previously naive to antiretroviral therapy. This study will involve approximately 200 centers from around the world to achieve a total randomized subject population of 1071 subjects. Patients will be randomly assigned to one of three groups: maraviroc (UK-427,857) 300 mg once daily added to zidovudine/lamivudine (300 mg/150 mg twice daily), Maraviroc (UK-427,857) 300 mg twice daily added to zidovudine/lamivudine (300 mg/150 mg twice daily) or efavirenz (600 mg once daily) added to zidovudine/lamivudine (300 mg/150 mg twice daily). The study will enroll over approximately an 18 month period (5 months Phase 2b run-in, 13 months Phase 3) with 96 weeks of treatment. This may be extended for an additional 3 years depending on the results at 96 weeks. Physical examinations will be performed at study entry, weeks 4, 8, 12, 16, 20, 24, 32, 40, 48, 60, 72, 84 and 96. Blood samples will also be taken at study entry, weeks 2, 4, 8, 12, 16, 20, 24, 32, 40, 48, 60, 72, 84 and 96. Additionally, blood samples will be drawn twice, at least 30 minutes apart, at weeks 2 and 48 for maraviroc (UK-427,857) pharmacokinetic analysis. As part of this clinical study a blood sample will be taken for non-anonymized pharmacogenetic analysis. Patients will undergo a 12-lead electrocardiogram at study entry, weeks 24, 48 and 96. A computerized tomography (CT) scan will also be performed, at selected centers, at study entry and week 96. Patients will be asked to complete a symptom distress questionnaire at study entry, weeks 12, 24, 48 and 96.
3,038 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 307 are open to participants now.
This study's enrollment of 916 is above the median of 96 across 2,252 interventional studies indexed under Acquired Immunodeficiency Syndrome.
Browse Acquired Immunodeficiency Syndrome studies →ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
Compared within Acquired Immunodeficiency Syndrome, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Maraviroc + Zidovudine/Lamivudine
Drug: Efavirenz + Zidovudine/Lamivudine
Following a review of the interim analysis data, the DSMB recommended to terminate the UK-427,857 300 mg QD arm based on pre-specified protocol non-inferiority criteria not being met for the QD arm versus efavirenz
Drug: Maraviroc (UK-427,857) + Zidovudine/Lamivudine
Drug pages: Maraviroc · Zidovudine · Lamivudine
maraviroc (UK-427,857) 300 mg once daily added to zidovudine/lamivudine (300 mg/150 mg twice daily)
Drug pages: Efavirenz · Zidovudine · Lamivudine
efavirenz (600 mg once daily) added to zidovudine/lamivudine (300 mg/150 mg twice daily)
Drug page: Maraviroc
maraviroc (UK-427,857) 300 mg twice daily added to zidovudine/lamivudine (300 mg/150 mg twice daily)
Percentage of Participants With Viral Load of Less Than 400 Copies/Milliliter [Copies/mL] and Less Than 50 Copies/mL of Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) at Week 48 for Full Analysis Set (FAS) Population
Time frame: Week 48
Percentage of Participants With Viral Load of Less Than 400 Copies/mL and Less Than 50 Copies/mL of HIV-1 RNA at Week 48 for Per Protocol (PP) Population
Percentage of participants with viral load of less than 400 copies/mL and less than 50 copies/mL of HIV-1 RNA were not analyzed for participants originally randomized to maraviroc once daily arm since after termination, focus was shifted from efficacy and safety to only safety as reflected in the abbreviated set of efficacy measures noted in the amended planned analysis.
Time frame: Week 48
Percentage of Participants With HIV-1 RNA Levels of Less Than 400 Copies/mL and Less Than 50 Copies/mL at Week 48 Analyzed Using Logistic Regression
Time frame: Week 48
Percentage of Participants With HIV-1 RNA Levels of Less Than 400 Copies/mL and Less Than 50 Copies/mL at Week 96 Analyzed Using Logistic Regression
Time frame: Week 96
Change From Baseline in Log 10-transformed Plasma Viral Load (HIV-1 RNA) Levels at Week 48 and 96
Change from baseline in log 10-transformed plasma viral load (HIV-1 RNA) levels (log10 copies/mL). Baseline value calculated as average of pre-dose measurements collected at screening, randomization, and immediately pre-dose.
Time frame: Baseline, Week 48, Week 96
Time-Averaged Difference (TAD) in log10-transformed HIV-1 RNA Levels
TAD from baseline was calculated as area under the curve (AUC) of HIV-1 RNA load (log10 copies/mL) divided by time period minus baseline HIV-1 RNA load (log10 copies/mL). Baseline value calculated as average of pre-dose measurements collected at screening, randomization, and immediately pre-dose. Data not analyzed for participants originally randomized to maraviroc once daily arm since after termination, focus was shifted from efficacy and safety to only safety as reflected in the abbreviated set of efficacy measures noted in the amended planned analysis.
Time frame: Baseline up to Week 48 and Week 96
Change From Baseline in Lymphocyte Cluster of Differentiation 4 (CD4) Count at Week 48 and 96
Baseline value calculated as the average of pre-dose measurements collected at screening and immediately pre-dose.
Time frame: Baseline, Week 48, Week 96
Change From Baseline in Lymphocyte Cluster of Differentiation 8 (CD8) Count at Week 48 and 96
Baseline value calculated as the average of pre-dose measurements collected at screening and immediately pre-dose. Change from baseline in lymphocyte CD8 count at Week 48 and 96 was not analyzed for participants originally randomized to maraviroc once daily arm since after termination, focus was shifted from efficacy and safety to only safety as reflected in the abbreviated set of efficacy measures noted in the amended planned analysis.
Time frame: Baseline, Week 48, Week 96
Time to Virologic Failure
Time to virologic failure based on observed HIV-1 RNA levels and failure events (death;permanent discontinuation of drug;lost to follow-up \[LTFU\];new anti-retroviral drug added \[except background drug change to drug of same class\];or on open label for early non-response or rebound). Failure:at Time 0 if level not \<400 copies/mL(2 consecutive visits) before events or last available visit;at time of earliest event if level \<400 copies/mL(2 consecutive visits);failure if level \>=400 copies/mL(2 consecutive visits) or 1 visit \>=400 copies/mL followed by permanent discontinuation of drug or LTFU.
Time frame: Week 48, Week 96
Number of Participants Per Tropism Status at Baseline and at the Time of Treatment Failure Through Week 48
Number of participants per tropism status (C-X-C chemokine receptor 5 {CCR5} \[R5\], C-X-C chemokine receptor type 4 {CXCR4} \[X4\], Dual/mixed \[DM\], or Non-reportable/Non-phenotypable \[NR/NP\]) at baseline and time of treatment failure analyzed through week 48 visit. Treatment failure: discontinuation due to insufficient clinical response. Tropism result was censored for participants with viral load \<500 copies/mL at time of treatment failure categorized as below lower limit of quantification (BLQ). The assessment for time of treatment failure was defined as last on treatment assessment.
Time frame: Baseline, time of failure through Week 48
Number of Participants Per Tropism Status at Baseline and at the Time of Treatment Failure Through Week 96
Number of participants per tropism status (R5, X4, DM, or NR/NP) at baseline and time of treatment failure analyzed through week 96 visit. Treatment failure defined as insufficient clinical response. Tropism result was censored for participants with viral load \<500 copies/mL at time of treatment failure categorized as BLQ. The assessment for time of treatment failure was defined as last on treatment assessment.
Time frame: Baseline, time of failure through Week 96
Number of Participants With Phenotypic Resistance at Time of Treatment Failure Through Week 48 and 96
Phenotypic resistance to nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) assessed at screening by Monogram Bioscience PhenoSense genotype (MBPSGT) assay, repeated if viral load \>500 copies/mL at treatment failure through week 48, 96. Phenotypic resistance to maraviroc was assumed in maraviroc treatment failures with X4-using virus and in R5 maraviroc treatment failures using Monogram Bioscience PhenoSense Entry Assay. Phenotypic resistance to zidovudine, lamivudine, efavirenz and maraviroc at time of failure was summarized.
Time frame: Screening, time of failure through Week 48, Week 96
Number of Participants With NRTI Associated Mutations at Time of Treatment Failure Through Week 48 and 96
Genotypic resistance to NRTIs was assessed by identification of relevant mutations at screening using MBPSGT assay and repeated for all participants with HIV-1 viral load more than 500 copies/mL at treatment failure through week 48 and week 96. Following mutations associated with NRTIs were summarized at time of failure: Any zidovudine/lamivudine (Zid/Lam), Any thymidine analogue-associated mutation (TAM), methionine (M) to valine/isoleucine (V/I) substitution at residue (r) 184 (M184V/I), lysine (K) to arginine (R) substitution at residue 65 (K65R) and any other NRTI mutations.
Time frame: Screening, time of failure through Week 48, Week 96
Number of Participants With Efavirenz Associated Mutations at Time of Treatment Failure Through Week 48 and 96
Genotypic resistance: mutations at screening by MBPSGT assay, repeated if viral load \>500 copies/mL at treatment failure through week 48, 96. Efavirenz mutation:lysine to aspargine at r103(K103N);tyrosine to cysteine/isoleucine at r181(Y181C/I);tyrosine to cysteine/leucine/histidine at r188(Y188C/L/H);glycine to alanine/serine at r190(G190A/S);valine to alanine to r106(V106A);leucine to isoleucine at r100(L100I);alanine to glycine at r98(A98G);lysine to glutamic acid at r101(K101E);valine to isoleucine at r108(V108I);proline to histidine at r225(P225H);methionine to leucine at r230(M230L).
Time frame: Screening, time of failure through Week 48, Week 96
Percentage of Participants With HIV-1 RNA Levels Less Than 50 Copies/mL at Week 48 and Week 96 by Overall Susceptibility Score (OSS) at Screening
Association between baseline resistance and virological response was assessed as percentage of participants with HIV-1RNA levels less than 50 copies/mL by OSS at screening. OSS categorized as 0, 1, 2, \>3 (maximum value of 6) and calculated as the sum of the net assessment of in-vitro phenotypic and genotypic susceptibility using a binary scoring system (0= resistant, 1= sensitive or susceptible) for each antiretroviral agent in OBT. Higher scores indicate greater susceptibility.
Time frame: Baseline, Week 48, Week 96
Percentage of Participants With Viral Load of Less Than 400 Copies/mL and Less Than 50 Copies/mL of HIV-1 RNA at Week 96
Time frame: Week 96
| Milestone | Maraviroc Once Daily + CBV (DB) | Maraviroc Twice Daily + CBV (DB and OL) | Efavirenz Once Daily + CBV (DB and OL) | Maraviroc Twice Daily + CBV (OL) | Maraviroc Twice Daily + CBV (SP) |
|---|---|---|---|---|---|
| Started | 177 | 368 | 372 | 0 | 0 |
| Treated | 174 | 360 | 361 | 0 | 0 |
| Completed | 0 | 202 | 202 | 0 | 0 |
| Not completed | 177 | 166 | 170 | 0 | 0 |
| Withdrew: Adverse event | 14 | 27 | 60 | 0 | 0 |
| Withdrew: Pregnancy | 0 | 7 | 9 | 0 | 0 |
| Withdrew: Participant defaulted | 11 | 40 | 36 | 0 | 0 |
| Withdrew: Lack of efficacy | 11 | 64 | 30 | 0 | 0 |
| Withdrew: Death | 1 | 2 | 2 | 0 | 0 |
| Withdrew: Randomized, not treated | 3 | 8 | 11 | 0 | 0 |
| Withdrew: Protocol violation | 2 | 18 | 22 | 0 | 0 |
| Withdrew: Terminated by sponsor | 135 | 0 | 0 | 0 | 0 |
| Milestone | Maraviroc Once Daily + CBV (DB) | Maraviroc Twice Daily + CBV (DB and OL) | Efavirenz Once Daily + CBV (DB and OL) | Maraviroc Twice Daily + CBV (OL) | Maraviroc Twice Daily + CBV (SP) |
|---|---|---|---|---|---|
| Started | 0 | 202 | 202 | 0 | 0 |
| Completed | 0 | 202 | 199 | 0 | 0 |
| Not completed | 0 | 0 | 3 | 0 | 0 |
| Withdrew: Did not enter open-label phase | 0 | 0 | 3 | 0 | 0 |
| Milestone | Maraviroc Once Daily + CBV (DB) | Maraviroc Twice Daily + CBV (DB and OL) | Efavirenz Once Daily + CBV (DB and OL) | Maraviroc Twice Daily + CBV (OL) | Maraviroc Twice Daily + CBV (SP) |
|---|---|---|---|---|---|
| Started | 0 | 202 | 199 | 130 | 0 |
| Completed | 0 | 177 | 158 | 65 | 0 |
| Not completed | 0 | 25 | 41 | 65 | 0 |
| Withdrew: Adverse event | 0 | 3 | 7 | 6 | 0 |
| Withdrew: Lack of efficacy | 0 | 7 | 2 | 20 | 0 |
| Withdrew: Pregnancy | 0 | 1 | 0 | 3 | 0 |
| Withdrew: Protocol violation | 0 | 6 | 13 | 16 | 0 |
| Withdrew: Participant defaulted | 0 | 6 | 16 | 20 | 0 |
| Withdrew: Death | 0 | 2 | 3 | 0 | 0 |
| Milestone | Maraviroc Once Daily + CBV (DB) | Maraviroc Twice Daily + CBV (DB and OL) | Efavirenz Once Daily + CBV (DB and OL) | Maraviroc Twice Daily + CBV (OL) | Maraviroc Twice Daily + CBV (SP) |
|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 127 |
| Completed | 0 | 0 | 0 | 0 | 94 |
| Not completed | 0 | 0 | 0 | 0 | 33 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 8 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 22 |
| Percentage of participants | Maraviroc Once Daily + CBV (DB), Then Twice Daily + CBV (OL) | Maraviroc Twice Daily + CBV (DB) | Efavirenz Once Daily + CBV (DB) |
|---|---|---|---|
| Less than 400 copies/mL | 61.5 | 70.6 | 73.1 |
| Less than 50 copies/mL | 55.8 | 65.3 | 69.3 |
Percentage of participants with viral load of less than 400 copies/mL and less than 50 copies/mL of HIV-1 RNA were not analyzed for participants originally randomized to maraviroc once daily arm since after termination, focus was shifted from efficacy and safety to only safety as reflected in the abbreviated set of efficacy measures noted in the amended planned analysis.
| Percentage of participants | Maraviroc Twice Daily + CBV (DB) | Efavirenz Once Daily + CBV (DB) |
|---|---|---|
| Less than 400 copies/mL | 75.00 | 78.27 |
| Less than 50 copies/mL | 70.00 | 74.44 |
| Percentage of participants | Maraviroc Once Daily + CBV (DB), Then Twice Daily + CBV (OL) | Maraviroc Twice Daily + CBV (DB) | Efavirenz Once Daily + CBV (DB) |
|---|---|---|---|
| Less than 400 copies/mL | 61.5 | 70.6 | 73.1 |
| Less than 50 copies/mL | 55.8 | 65.3 | 69.3 |
| Percentage of participants | Maraviroc Once Daily + CBV (DB), Then Twice Daily + CBV (OL) | Maraviroc Twice Daily + CBV (DB) | Efavirenz Once Daily + CBV (DB) |
|---|---|---|---|
| Less than 400 copies/mL | 52.9 | 61.4 | 64.5 |
| Less than 50 copies/mL | 48.3 | 56.9 | 62.6 |
Change from baseline in log 10-transformed plasma viral load (HIV-1 RNA) levels (log10 copies/mL). Baseline value calculated as average of pre-dose measurements collected at screening, randomization, and immediately pre-dose.
| log10 copies/mL | Maraviroc Once Daily + CBV (DB), Then Twice Daily + CBV (OL) | Maraviroc Twice Daily + CBV (DB) | Efavirenz Once Daily + CBV (DB) |
|---|---|---|---|
| Baseline | 4.899 ± 0.6273 | 4.851 ± 0.6511 | 4.857 ± 0.6156 |
| Change at Week 48 | -2.665 ± 0.9454 | -2.240 ± 1.484 | -2.347 ± 1.455 |
| Change at Week 96 | -2.565 ± 0.9731 | -1.961 ± 1.575 | -2.053 ± 1.564 |
TAD from baseline was calculated as area under the curve (AUC) of HIV-1 RNA load (log10 copies/mL) divided by time period minus baseline HIV-1 RNA load (log10 copies/mL). Baseline value calculated as average of pre-dose measurements collected at screening, randomization, and immediately pre-dose. Data not analyzed for participants originally randomized to maraviroc once daily arm since after termination, focus was shifted from efficacy and safety to only safety as reflected in the abbreviated set of efficacy measures noted in the amended planned analysis.
| log10 copies/mL | Maraviroc Twice Daily + CBV (DB) | Efavirenz Once Daily + CBV (DB) |
|---|---|---|
| Week 48 | -2.152 ± 0.0713 | -2.262 ± 0.0714 |
| Week 96 | -1.945 ± 0.0798 | -2.034 ± 0.0800 |
Baseline value calculated as the average of pre-dose measurements collected at screening and immediately pre-dose.
| cells per microliter (cells/µL) | Maraviroc Once Daily + CBV (DB), Then Twice Daily + CBV (OL) | Maraviroc Twice Daily + CBV (DB) | Efavirenz Once Daily + CBV (DB) |
|---|---|---|---|
| Baseline | 274.1 ± 175.45 | 264.70 ± 153.508 | 271.87 ± 133.491 |
| Change at Week 48 | 172.50 ± 205.561 | 169.53 ± 134.409 | 143.52 ± 124.931 |
| Change at Week 96 | 183.75 ± 166.454 | 206.31 ± 152.682 | 171.50 ± 149.163 |
Baseline value calculated as the average of pre-dose measurements collected at screening and immediately pre-dose. Change from baseline in lymphocyte CD8 count at Week 48 and 96 was not analyzed for participants originally randomized to maraviroc once daily arm since after termination, focus was shifted from efficacy and safety to only safety as reflected in the abbreviated set of efficacy measures noted in the amended planned analysis.
| cells/µL | Maraviroc Twice Daily + CBV (DB) | Efavirenz Once Daily + CBV (DB) |
|---|---|---|
| Baseline | 938.80 ± 503.392 | 935.78 ± 476.607 |
| Change at Week 48 | 38.34 ± 397.503 | -126.83 ± 374.494 |
| Change at Week 96 | 20.74 ± 412.081 | -150.27 ± 389.996 |
Time to virologic failure based on observed HIV-1 RNA levels and failure events (death;permanent discontinuation of drug;lost to follow-up \[LTFU\];new anti-retroviral drug added \[except background drug change to drug of same class\];or on open label for early non-response or rebound). Failure:at Time 0 if level not \<400 copies/mL(2 consecutive visits) before events or last available visit;at time of earliest event if level \<400 copies/mL(2 consecutive visits);failure if level \>=400 copies/mL(2 consecutive visits) or 1 visit \>=400 copies/mL followed by permanent discontinuation of drug or LTFU.
| days | Maraviroc Twice Daily + CBV (DB) | Efavirenz Once Daily + CBV (DB) |
|---|---|---|
| Week 48 | NA (354 to NA) | NA (364 to NA) |
| Week 96 | NA (NA to NA) | NA (691 to NA) |
Number of participants per tropism status (C-X-C chemokine receptor 5 {CCR5} \[R5\], C-X-C chemokine receptor type 4 {CXCR4} \[X4\], Dual/mixed \[DM\], or Non-reportable/Non-phenotypable \[NR/NP\]) at baseline and time of treatment failure analyzed through week 48 visit. Treatment failure: discontinuation due to insufficient clinical response. Tropism result was censored for participants with viral load \<500 copies/mL at time of treatment failure categorized as below lower limit of quantification (BLQ). The assessment for time of treatment failure was defined as last on treatment assessment.
| participants | Maraviroc Once Daily + CBV (DB), Then Twice Daily + CBV (OL) | Maraviroc Twice Daily + CBV (DB) | Efavirenz Once Daily + CBV (DB) |
|---|---|---|---|
| Baseline: R5; Treatment failure: R5 | 5 | 11 | 6 |
| Baseline: R5; Treatment failure: X4 | 0 | 0 | 0 |
| Baseline: R5; Treatment failure: DM | 3 | 10 | 0 |
| Baseline: R5; Treatment failure: NR/NP | 5 | 5 | 4 |
| Baseline: DM; Treatment failure: R5 | 0 | 1 | 0 |
| Baseline: DM; Treatment failure: X4 | 0 | 2 | 0 |
| Baseline: DM; Treatment failure: DM | 5 | 4 | 0 |
| Baseline: DM; Treatment failure: NR/NP | 0 | 0 | 0 |
Number of participants per tropism status (R5, X4, DM, or NR/NP) at baseline and time of treatment failure analyzed through week 96 visit. Treatment failure defined as insufficient clinical response. Tropism result was censored for participants with viral load \<500 copies/mL at time of treatment failure categorized as BLQ. The assessment for time of treatment failure was defined as last on treatment assessment.
| participants | Maraviroc Once Daily + CBV (DB), Then Twice Daily + CBV (OL) | Maraviroc Twice Daily + CBV (DB) | Efavirenz Once Daily + CBV (DB) |
|---|---|---|---|
| Baseline: R5; Treatment failure: R5 | 9 | 14 | 10 |
| Baseline: R5; Treatment failure: X4 | 0 | 1 | 0 |
| Baseline: R5; Treatment failure: DM | 4 | 11 | 0 |
| Baseline: R5; Treatment failure: NR/NP | 6 | 7 | 5 |
| Baseline: DM; Treatment failure: R5 | 0 | 1 | 1 |
| Baseline: DM; Treatment failure: X4 | 0 | 2 | 0 |
| Baseline: DM; Treatment failure: DM | 5 | 4 | 0 |
| Baseline: DM; Treatment failure: NR/NP | 0 | 0 | 0 |
| Baseline: NR/NP; Treatment failure: R5 | 0 | 1 | 0 |
| Baseline: NR/NP; Treatment failure: X4 | 0 | 0 | 0 |
| Baseline: NR/NP; Treatment failure: DM | 0 | 0 | 0 |
| Baseline: NR/NP; Treatment failure: NR/NP | 0 | 1 | 0 |
Phenotypic resistance to nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) assessed at screening by Monogram Bioscience PhenoSense genotype (MBPSGT) assay, repeated if viral load \>500 copies/mL at treatment failure through week 48, 96. Phenotypic resistance to maraviroc was assumed in maraviroc treatment failures with X4-using virus and in R5 maraviroc treatment failures using Monogram Bioscience PhenoSense Entry Assay. Phenotypic resistance to zidovudine, lamivudine, efavirenz and maraviroc at time of failure was summarized.
| participants | Maraviroc Once Daily + CBV (DB), Then Twice Daily + CBV (OL) | Maraviroc Twice Daily + CBV (DB) | Efavirenz Once Daily + CBV (DB) |
|---|---|---|---|
| Resistance to Zidovudine: Week 48 (n= 20, 43, 15) | 0 | 0 | 0 |
| Resistance to Lamivudine: Week 48 (n= 20, 43, 15) | 14 | 27 | 3 |
| Resistance to Efavirenz: Week 48 (n= 20, 43, 15) | 0 | 0 | 7 |
| Resistance to Maraviroc: Week 48 (n= 20, 43, 15) | NA | 12 | NA |
| Resistance to Zidovudine: Week 96 (n= 27, 55, 23) | 0 | 0 | 0 |
| Resistance to Lamivudine: Week 96 (n= 27, 55, 23) | 20 | 33 | 8 |
| Resistance to Efavirenz: Week 96 (n= 27, 55, 23) | 0 | 0 | 13 |
| Resistance to Maraviroc: Week 96 (n= 27, 55, 23) | NA | NA | NA |
Genotypic resistance to NRTIs was assessed by identification of relevant mutations at screening using MBPSGT assay and repeated for all participants with HIV-1 viral load more than 500 copies/mL at treatment failure through week 48 and week 96. Following mutations associated with NRTIs were summarized at time of failure: Any zidovudine/lamivudine (Zid/Lam), Any thymidine analogue-associated mutation (TAM), methionine (M) to valine/isoleucine (V/I) substitution at residue (r) 184 (M184V/I), lysine (K) to arginine (R) substitution at residue 65 (K65R) and any other NRTI mutations.
| participants | Maraviroc Once Daily + CBV (DB), Then Twice Daily + CBV (OL) | Maraviroc Twice Daily + CBV (DB) | Efavirenz Once Daily + CBV (DB) |
|---|---|---|---|
| Any Zid/Lam Mutation: Week 48 (n= 20, 43, 15) | 14 | 27 | 3 |
| Any TAM Mutation: Week 48 (n= 20, 43, 15) | 1 | 6 | 0 |
| K65R Mutation: Week 48 (n= 20, 43, 15) | 0 | 1 | 0 |
| M184V/I Mutation: Week 48 (n= 20, 43, 15) | 14 | 27 | 3 |
| Other NRTI Mutation: Week 48 (n= 20, 43, 15) | 0 | 1 | 0 |
| Any Zid/Lam Mutation: Week 96 (n= 27, 55, 23) | 20 | 33 | 8 |
| Any TAM Mutation: Week 96 (n= 27, 55, 23) | 3 | 6 | 2 |
| K65R Mutation: Week 96 (n= 27, 55, 23) | 0 | 1 | 0 |
| M184V/I Mutation: Week 96 (n= 27, 55, 23) | 20 | 33 | 8 |
| Other NRTI Mutation: Week 96 (n= 27, 55, 23) | 0 | 1 | 0 |
Genotypic resistance: mutations at screening by MBPSGT assay, repeated if viral load \>500 copies/mL at treatment failure through week 48, 96. Efavirenz mutation:lysine to aspargine at r103(K103N);tyrosine to cysteine/isoleucine at r181(Y181C/I);tyrosine to cysteine/leucine/histidine at r188(Y188C/L/H);glycine to alanine/serine at r190(G190A/S);valine to alanine to r106(V106A);leucine to isoleucine at r100(L100I);alanine to glycine at r98(A98G);lysine to glutamic acid at r101(K101E);valine to isoleucine at r108(V108I);proline to histidine at r225(P225H);methionine to leucine at r230(M230L).
| participants | Maraviroc Twice Daily + CBV (DB) | Efavirenz Once Daily + CBV (DB) |
|---|---|---|
| L100I Mutation: Week 48 (n= 43, 15) | 0 | 0 |
| K103N Mutation: Week 48 (n= 43, 15) | 0 | 6 |
| V106M Mutation: Week 48 (n= 43, 15) | 0 | 0 |
| V108I Mutation: Week 48 (n= 43, 15) | 1 | 0 |
| Y181C/I Mutation: Week 48 (n= 43, 15) | 0 | 0 |
| Y188L Mutation: Week 48 (n= 43, 15) | 0 | 0 |
| G190S/A Mutation: Week 48 (n= 43, 15) | 0 | 1 |
| P225H Mutation: Week 48 (n= 43, 15) | 0 | 0 |
| L100I Mutation: Week 96 (n= 55, 23) | 0 | 0 |
| K103N Mutation: Week 96 (n= 55, 23) | 0 | 12 |
| V106M Mutation: Week 96 (n= 55, 23) | 0 | 1 |
| V108I Mutation: Week 96 (n= 55, 23) | 1 | 1 |
| Y181C/I Mutation: Week 96 (n= 55, 23) | 0 | 0 |
| Y188L Mutation: Week 96 (n= 55, 23) | 0 | 0 |
| G190S/A Mutation: Week 96 (n= 55, 23) | 0 | 2 |
| P225H Mutation: Week 96 (n= 55, 23) | 0 | 1 |
Association between baseline resistance and virological response was assessed as percentage of participants with HIV-1RNA levels less than 50 copies/mL by OSS at screening. OSS categorized as 0, 1, 2, \>3 (maximum value of 6) and calculated as the sum of the net assessment of in-vitro phenotypic and genotypic susceptibility using a binary scoring system (0= resistant, 1= sensitive or susceptible) for each antiretroviral agent in OBT. Higher scores indicate greater susceptibility.
No measurements were reported for this outcome.
| Percentage of participants | Maraviroc Once Daily + CBV (DB), Then Twice Daily + CBV (OL) | Maraviroc Twice Daily + CBV (DB) | Efavirenz Once Daily + CBV (DB) |
|---|---|---|---|
| Less than 400 copies/mL | 52.9 | 61.4 | 64.5 |
| Less than 50 copies/mL | 48.3 | 56.9 | 62.6 |
Percentage of participants with HIV-1 RNA levels of less than 400 copies/mL and less than 50 copies/mL were not analyzed for maraviroc once daily, then twice daily arm in order to avoid misinterpretation due to possible bias due to the fact that only a non-random sample of participants in the terminated arm were re-assayed with ESTA.
| Percentage of participants | Maraviroc Twice Daily + CBV (DB) | Efavirenz Once Daily + CBV (DB) |
|---|---|---|
| Less than 400 copies/mL | 73.3 | 72.3 |
| Less than 50 copies/mL | 68.5 | 68.3 |
Percentage of participants with HIV-1 RNA levels of less than 400 copies/mL and less than 50 copies/mL were not analyzed for maraviroc once daily, then twice daily arm in order to avoid misinterpretation due to possible bias due to the fact that only a non-random sample of participants in the terminated arm were re-assayed with ESTA.
| Percentage of participants | Maraviroc Twice Daily + CBV (DB) | Efavirenz Once Daily + CBV (DB) |
|---|---|---|
| Less than 400 copies/mL | 64.0 | 64.4 |
| Less than 50 copies/mL | 58.8 | 62.7 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Maraviroc Once Daily + CBV (DB), Then Twice Daily + CBV (OL) | — | 47/174 (27%) | 151/174 (86.8%) |
| Maraviroc Twice Daily + CBV (DB and OL) | — | 77/360 (21.4%) | 319/360 (88.6%) |
| Efavirenz Once Daily + CBV (DB and OL) | — | 82/361 (22.7%) | 327/361 (90.6%) |
| Maraviroc Twice Daily + CBV (SP) | — | 4/127 (3.1%) | 0/127 (0%) |
| Event | Maraviroc Once Daily + CBV (DB), Then Twice Daily + CBV (OL) | Maraviroc Twice Daily + CBV (DB and OL) | Efavirenz Once Daily + CBV (DB and OL) | Maraviroc Twice Daily + CBV (SP) |
|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 6/174 | 7/360 | 6/361 | 0/127 |
| PyrexiaGeneral disorders | 4/174 | 4/360 | 5/361 | 0/127 |
| PregnancyPregnancy, puerperium and perinatal conditions | 3/174 | 5/360 | 8/361 | 0/127 |
| NeutropeniaBlood and lymphatic system disorders | 3/174 | 2/360 | 2/361 | 0/127 |
| PneumoniaInfections and infestations | 1/174 | 3/360 | 5/361 | 0/127 |
| DiarrhoeaGastrointestinal disorders | 2/174 | 2/360 | 0/361 | 0/127 |
| Chest painGeneral disorders | 2/174 | 0/360 | 0/361 | 0/127 |
| Jaw fractureInjury, poisoning and procedural complications | 2/174 | 0/360 | 0/361 | 0/127 |
| Suicide attemptPsychiatric disorders | 2/174 | 0/360 | 2/361 | 0/127 |
| Abdominal painGastrointestinal disorders | 1/174 | 4/360 | 1/361 | 0/127 |
| Event | Maraviroc Once Daily + CBV (DB), Then Twice Daily + CBV (OL) | Maraviroc Twice Daily + CBV (DB and OL) | Efavirenz Once Daily + CBV (DB and OL) | Maraviroc Twice Daily + CBV (SP) |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 60/174 | 138/360 | 132/361 | 0/127 |
| DizzinessNervous system disorders | 25/174 | 62/360 | 116/361 | 0/127 |
| DiarrhoeaGastrointestinal disorders | 46/174 | 90/360 | 111/361 | 0/127 |
| HeadacheNervous system disorders | 44/174 | 109/360 | 105/361 | 0/127 |
| Upper respiratory tract infectionInfections and infestations | 32/174 | 82/360 | 78/361 | 0/127 |
| FatigueGeneral disorders | 37/174 | 64/360 | 60/361 | 0/127 |
| NasopharyngitisInfections and infestations | 24/174 | 70/360 | 48/361 | 0/127 |
| CoughRespiratory, thoracic and mediastinal disorders | 22/174 | 51/360 | 66/361 | 0/127 |
| BronchitisInfections and infestations | 28/174 | 64/360 | 49/361 | 0/127 |
| Abdominal painGastrointestinal disorders | 30/174 | 53/360 | 53/361 | 0/127 |
| Age, Customized(participants) | Maraviroc Once Daily + CBV (DB) | Maraviroc Twice Daily + CBV (DB and OL) | Efavirenz Once Daily + CBV (DB and OL) | Total |
|---|---|---|---|---|
| Less than 18 years | 0 | 0 | 0 | 0 |
| 18 to 24 years | 17 | 24 | 25 | 66 |
| 25 to 34 years | 47 | 147 | 120 | 314 |
| 35 to 44 years | 73 | 117 | 141 | 331 |
| 45 to 54 years | 29 | 56 | 55 | 140 |
| 55 to 64 years | 7 | 14 | 15 | 36 |
| Greater than or equal to 65 years | 1 | 2 | 5 | 8 |
| Sex: Female, Male(Participants) | Maraviroc Once Daily + CBV (DB) | Maraviroc Twice Daily + CBV (DB and OL) | Efavirenz Once Daily + CBV (DB and OL) | Total |
|---|---|---|---|---|
| Female | 44 | 104 | 102 | 250 |
| Male | 130 | 256 | 259 | 645 |
Showing the first 100 of 144 sites across 14 countries. Choose a country and city above to see the rest.
The record gives a start of Nov 2004, a primary completion of Apr 2007 and a completion of Dec 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2012, 5 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Maraviroc · Zidovudine · Lamivudine
Acquired Immunodeficiency Syndrome →